CDC panel recommends Merck's RSV shot for infants, praised for effectiveness, some safety concerns

From CNBC: 2025-06-26 13:45:00

The new government panel of vaccine advisors recommended Merck’s shot for infants to protect against respiratory syncytial virus. The shot, Enflonsia, will compete with a rival shot from Sanofi and AstraZeneca. Merck’s shot reduces RSV-related hospitalizations by over 84%. Some panel members questioned its safety, while others praised its effectiveness.

The Advisory Committee on Immunization Practices voted unanimously to include Merck’s shot in the recommended childhood immunizations list. The signoff allows Merck to launch the shot ahead of the RSV season, which typically starts in fall. The shot is considered a significant advance in medical science, with experts urging its approval to protect children’s health.

Merck’s Enflonsia shot received approval from the FDA earlier this month. Panel members emphasized its safety and effectiveness, with some vaccine critics expressing concerns about its readiness for all healthy babies. The shot is recommended for infants aged 8 months or younger entering their first RSV season. The FDA and ACIP have thoroughly reviewed the shot for safety and efficacy.



Read more at CNBC: RFK Jr. CDC vaccine panel backs Merck RSV shot for infants